Canbiola Announces Closing of Green Grow Farms Acquisition
Hicksville, NY - (NewMediaWire) - January 14, 2020 - Canbiola, Inc. (OTCQB: CANB) (“Canbiola” or the “Company”), a developer, manufacturer, and supplier of a variety of hemp-derived THC-Free Cannabidiol (CBD) Isolate products such as oils, drops/tinctures, creams, moisturizers, chews, and capsules, announced today the closing of the previously announced agreement for an all-stock transaction to acquire 51% of Green Grow Farms Inc.
Green Grow Farms Inc is licensed by New York State to grow hemp under the Hemp Research Pilot Program. Green Grow Farms grows industrial hemp for grain, flower, and CBD. Green Grow Farms has successfully grown and harvested 6 Acres on two farms in Calverton, NY this year, yielding in excess of 12,000 pounds of dried biomass. The current New York inventory consists of Suver Haze and Sweetened varieties with CBD content ranging from 13% to 16%.
Green Grow Farms is expanding into extraction and processing in a strategic and calculated manner as we anticipate the extraordinary demand for CBD related products to continue.
The close of this transaction furthers the full vertical integration goals of Canbiola. The Company currently has successful consumer brands under the Pure Leaf Oil, Seven Chakras and Canbiola names and has a full, company-owned production facility in Lacey, Washington where all products are manufactured, and white label services are provided.
Canbiola Chief Executive Officer, Marco Alfonsi, commented, “We are pleased to have closed this acquisition in a timely manner as we continue to move our company forward. Green Grow Farms is a key component in moving forward with our growth initiatives, to that end, we will be providing our shareholders with an annual recap for 2019 and outlining our 2020 goals later this week.”
About Canbiola, Inc.
Canbiola, Inc. (OTCQB: CANB) is a vertically integrated conglomerate specializing in the manufacturing, formulation, and sale of THC-Free Cannabidiol (CBD) Isolate products such as oils, drops/tinctures, gels, creams, moisturizers, chews, and capsules. All Canbiola products are organic and Non-GMO, free of impurities and contaminants, and formulated with the finest ingredients to the highest manufacturing standards. All products are certified for purity and accuracy by third-party laboratory verification.
Canbiola pursues an aggressive growth strategy through the continual development of proprietary products and the expansion of its offerings via strategic acquisitions in the healthcare and CBD industries.
Canbiola has created several innovative CBD product lines, marketed through targeted channels including:
The Canbiola clinical line, which is marketed and promoted through healthcare practitioners in the medical setting.
The Pure Leaf Oil (consumer brand) and Seven Chakras (spa brand) lines are sold through both online and brick & mortar retail outlets.
Canbiola’s state-of-the-art manufacturing facility in Lacey, WA is operated by Pure Health Products LLC (PHP), a wholly-owned subsidiary that produces all of the Company’s CBD Isolate products, in addition to providing private label and white label solutions for companies looking to add high-quality CBD items to their offerings. Canbiola is passionate about improving people’s lives and we take pride in providing pure CBD products infused with organic and natural ingredients. We want customers to know that they are buying lab-tested, high-quality natural products at a great price.
Canbiola’s Radical Tactical LLC subsidiary produces CBD products in other forms including vapes and gums.
Duramed Inc. and Duramed NJ LLC, wholly-owned subsidiaries of Canbiola, further the mission of providing innovative products designed to improve people’s lives, aiming to reduce their use of opioid substances through the utilization of durable medical devices. This product line includes a wearable low-intensity ultrasound SAM (Sustained Acoustic Medicine) device delivering multi-hour treatment intended to accelerate healing, improve function for musculoskeletal injuries (muscle, tendon, ligament) and reduce chronic pain (without opioid pain medication).
With the creation of its newest wholly-owned subsidiary, NY Hemp Depot LLC, Canbiola has further attained vertical integration, allowing it to fully control the supply chain from seed to sale, develop customized products and maximize profit margins. Through the utilization of its newly acquired NY State Hemp Cultivation License, the Company contracts with farmers throughout the state of NY to cultivate specific strains of hemp, which is then processed into CBD Isolate products to Canbiola’s exacting manufacturing standards and specifications at the Company’s laboratory and production facility.
For more information about Canbiola, Inc., please visit: Canbiola.com
Forward-looking statements and risks and uncertainties discussed in this letter contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price.
Follow Canbiola on:
Instagram @canbiola.inc or @canbiola_cbd or @canbiola_medical_cbd
Investors and Media: